Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial

The effects of dapagliflozin (DAP) and pioglitazone (PIO) on body weight and glycaemic control were compared in patients with type 2 diabetes mellitus. Seventy‐one patients on PIO were either switched to DAP (n = 36) at 5 mg per day or continued on PIO (n = 35). Primary endpoints were superiority of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Obes Metab
Hlavní autoři: Cho, Kyu Yong, Nakamura, Akinobu, Omori, Kazuno, Takase, Takahiro, Miya, Aika, Manda, Naoki, Kurihara, Yoshio, Aoki, Shin, Atsumi, Tatsuya, Miyoshi, Hideaki
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2018
Témata:
Brief Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6587523/
https://ncbi.nlm.nih.gov/pubmed/30311367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13557
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky